527 evidence-based articles, checked against primary sources.

Prior authorization is how a plan decides whether it will pay for a GLP-1 — and it is designed to say no more often than yes. Here is the documentation plans typically want, the coverage-criteria document you have a right to see, and how to build a request that matches it honestly.

Wegovy's list price is $1,349.02 a package, but almost nobody pays it. Commercially insured patients can pay as little as $25 a month with the savings card; cash-pay patients buying direct from NovoCare Pharmacy pay from $149 to $399 a month depending on form and dose. Medicare and Medicaid are excluded from the savings card — but a separate federal $50/month program opened July 1, 2026. Here is what each route actually costs, who is shut out of it, and the exact questions to ask your plan.

Compounded tirzepatide and Zepbound are not the same purchase. One is an FDA-approved product with a reviewed label, verified potency and a manufacturer who is accountable; the other is a pharmacy preparation FDA has never evaluated, usually supplied as a vial and syringe, sometimes with added ingredients that were never in the approved drug. This guide lays out exactly what differs, what FDA and Eli Lilly have said and done, and what the price gap actually looks like now that Lilly sells cash-pay Zepbound directly.

The list price, the insured copay and the cash price of Ozempic are three completely different numbers. We separate them, show who qualifies for each route, and explain the Medicare and Medicaid rule that catches almost everyone out.

Ozempic starts at 0.25 mg once weekly for four weeks, then steps up in four-week intervals to 0.5 mg, 1 mg and a 2 mg maximum. The slow ramp exists to let the gut adapt — it is the reason most people tolerate the drug at all. Here is the published schedule, what each step feels like, and the questions to bring to your prescriber.

The FDA label for Zepbound (tirzepatide) starts everyone at 2.5 mg once weekly for four weeks, then steps up in 2.5 mg increments no sooner than every four weeks. Maintenance is 5, 10 or 15 mg for weight; 10 or 15 mg for sleep apnea. Here is the ladder, the vial-versus-pen tradeoff, prices checked against Lilly's own pages, and what the withdrawal data show.

Weight regain after stopping a GLP-1 is the expected biological result, not a personal failure. Here is what STEP 1 and SURMOUNT-4 actually measured, why appetite comes back, what may blunt the regain, and the questions to ask a prescriber if cost, side effects or coverage are forcing the decision.

A concrete answer instead of "it depends": which menopause hormone products commercial plans and Medicare Part D usually pay for, which they almost never pay for and why, what the generics actually cost in cash (checked July 2026), and the four levers — generic substitution, tier check, formulary exception, copay card — that genuinely move a bill.

Fewer than 1% of denied in-network claims are ever appealed. Yet insurers reversed themselves on about a third of the appeals they did receive in 2024, and where independent external reviewers publish their results, they overturn close to half of what reaches them. Here's the ladder, the deadlines, and what to do — with July 2026 prices — if the appeal still fails.

Telehealth can be a genuinely good way to start hormone therapy — or a way to get sold a compounded pellet you cannot take back out. This guide gives you the red flags, the contraindications a real service must ask about, and the exact questions to ask before you pay.

The same drug can be covered under one brand name and excluded under another. We explain why, what Medicare's new $50 GLP-1 Bridge does and does not do, how prior authorization and step therapy actually work, what the manufacturers' self-pay prices really are in July 2026, and the exact wording to ask your insurer about.

Wegovy's label lays out a five-step, 16-week escalation from 0.25 mg to a 1.7 mg or 2.4 mg maintenance dose — with a 7.2 mg high-dose option and an oral tablet now on the label too. This is a reference page, not instructions: your prescriber sets your dose. We cover why the ramp exists, why slowing it down is common and legitimate, what a month costs right now, and why weight usually returns after stopping.

Formication — the sensation of ants or insects crawling on or under the skin when nothing is there — is an uncommon but genuine menopause symptom that is routinely dismissed. We explain the likely nerve mechanism, the non-hormonal causes you must not miss (B12, iron, thyroid, diabetes, shingles, alcohol, medications), what actually eases it, and exactly when to be seen.

Why does skin suddenly react to a moisturiser you have used for a decade? Estrogen loss thins the skin, reduces collagen by roughly 30% in the first five years after menopause and impairs the barrier. This guide separates the ordinary midlife rashes — contact dermatitis, eczema flares, rosacea, hives, seborrhoeic dermatitis, itch without a rash — from the red flags that need a doctor now.

Most uterine polyps are benign, but the odds change with menopausal status and bleeding. A clear, honest guide to symptoms, cancer risk, scans, hysteroscopic removal, recovery and recurrence — written for women at midlife.

Dizziness gets waved through as "just perimenopause" more often than it should be. Here's the honest version: the plausible hormonal links, the far more common non-hormonal causes at this age (anaemia from heavy periods, low blood pressure, BPPV, thyroid disease, arrhythmia), how to tell lightheadedness from vertigo from near-fainting, and the symptoms that mean you should be seen today.

Tinnitus becomes more common in the 40s and 50s, the same years perimenopause arrives. The honest answer is that a direct hormonal cause is unproven. But the plausible routes — poor sleep, anxiety, and the quiet start of age-related hearing loss — are real, and one of them is treatable. This guide separates what has evidence from what does not, and names the red flags that need same-week (or same-day) assessment.

Any vaginal bleeding 12 or more months after your final period is never normal — not a spot, not once, not "just a bit of pink." Most of the time the cause is harmless, but about 9-10% of women with postmenopausal bleeding have endometrial cancer, which is highly curable when caught early. Here is what causes it, what the workup actually involves, and what to say if you're brushed off.